Key Points
- Pluri director Alexandre Weinstein Manieu purchased 833,334 shares at $1.50 each, investing $1.25 million and increasing his direct ownership by 66.67% to 2.08 million shares.
- Pluri shares were reported up 6.2%, opening at $1.19. The stock has traded between $0.85 and $4.87 over the past year, while its market capitalization is approximately $15 million.
- The company reported a quarterly loss of $0.54 per share, better than analysts’ expected $0.66 loss, but revenue of $0.34 million fell short of the $0.66 million consensus estimate. Analyst sentiment remains negative, with a consensus “Sell” rating.
Pluri Inc. (NASDAQ:PLUR - Get Free Report) Director Alexandre Weinstein Manieu acquired 833,334 shares of the company's stock in a transaction dated Friday, October 23rd. The stock was purchased at an average cost of $1.50 per share, for a total transaction of $1,250,001.00. Following the purchase, the director directly owned 2,083,334 shares in the company, valued at approximately $3,125,001. This represents a 66.67% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through this link.
Pluri Stock Up 6.2%
Shares of Pluri stock opened at $1.19 on Wednesday. The business has a fifty day simple moving average of $1.19 and a 200-day simple moving average of $2.41. Pluri Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $4.87. The firm has a market cap of $15.01 million, a price-to-earnings ratio of -0.49 and a beta of 0.69.
Pluri (NASDAQ:PLUR - Get Free Report) last announced its earnings results on Thursday, September 10th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.12. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.66 million.
Analysts Set New Price Targets
Separately, Weiss Ratings downgraded shares of Pluri from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, August 26th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, Pluri has a consensus rating of "Sell".
Read Our Latest Report on Pluri
Pluri Company Profile
(
Get Free Report)
Pluri Inc is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company's platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification.
Pluri's health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
